uniQure QURE 深 滬
交易中 09-17 10:10:33 美东时间
14.88
+0.410
+2.83%
華盛通- 最 高15.065
- 今 開14.56
- 成交量 11.94万股
- 最 低 14.51
- 昨 收 14.47
- 總市值 8.16亿
- 52周最高 19.18
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 4.45
- 委 比 40.85%
- 總股本 5486.69万
- 歷史最高 82.49
- 量 比 1.29
- 振 幅 3.84%
- 歷史最低 3.73
- 每 手 1
- 風險率 4.01%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多IREN tops week's financial gainers, Circle Internet falls the most
This week's biggest movers among financial stocks included crypto-linked firms, fintechs and housing-related names. Overall, the Financial Select Sector SPDR ETF (XLF) dipped 1.5% in the past five ses...
09-06 22:10
HC Wainwright & Co. Reiterates Buy on uniQure, Maintains $70 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates uniQure (NASDAQ:QURE) with a Buy and maintains $70 price target.
09-05 22:38
uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease
Initial results from uniQure's AMT-191 Phase I/IIa trial for Fabry disease show all four patients in the first cohort achieved 27- to 208-fold increases in α-Gal A activity. All patients discontinued enzyme replacement therapy (ERT) with stable lyso-Gb3 levels. AMT-191 demonstrated a manageable safety profile at the highest dose, though some adverse events were observed. Updated results are expected in the first half of 2026.
09-05 11:05
FDA Outlines Process To Speed Up Rare Disease Therapy Approvals
FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questions on development impact.
09-05 02:50
Chardan Capital Maintains Buy on uniQure, Maintains $35 Price Target
Chardan Capital analyst Daniil Gataulin maintains uniQure (NASDAQ:QURE) with a Buy and maintains $35 price target.
08-29 20:24
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction
Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA vaccine oversight.
08-11 20:45
Biotech sector slips amid reported return of ousted FDA official
Shares of several biotech firms fell in premarket trading Monday after reports that ousted U.S. Food and Drug Administration vaccine regulator Vinay Prasad will return to the agency. Prasad, who had o...
08-11 18:25
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?
Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.
07-30 23:07
美股大行评级 | 潜在涨幅36%！花旗上调Coinbase目标价升至505美元；摩根大通维持迪士尼"超配"评级，目标价升至138美元
今日重点评级关注：花旗：维持Apellis Pharmaceuticals"买入"评级，目标价从41美元升至46美元；杰富瑞：维持Kiniksa Pharmaceuticals"买入"评级，目标价从45美元升至54美元
07-30 09:36
Chardan Capital Maintains Buy on uniQure, Lowers Price Target to $35
Chardan Capital analyst Daniil Gataulin maintains uniQure (NASDAQ:QURE) with a Buy and lowers the price target from $38 to $35.
07-30 06:18
